Artificial Lung Devices Market Overview
The Artificial Lung Devices Market is expanding as the prevalence of respiratory diseases increases and healthcare providers adopt advanced technologies for respiratory support. Growing demand for extracorporeal life support, improvements in device miniaturization, AI-assisted monitoring, and rising healthcare expenditure are supporting market growth. The increasing shift toward home healthcare and development of portable artificial lung devices are also creating new opportunities.
According to the WiseGuyReports report, the Artificial Lung Devices Market was valued at USD 2.1 billion in 2024 and is expected to grow from USD 2.3 billion in 2025 to USD 4.5 billion by 2035, registering a CAGR of 7.1% from 2025 to 2035. North America is expected to remain the leading regional market, valued at USD 1.2 billion in 2024 and projected to reach USD 2.4 billion by 2035. Invasive Ventilation was valued at USD 700 million in 2024 and is projected to reach USD 1.4 billion by 2035, maintaining a dominant position among product types.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/artificial-lung-devices-market
Key players in the Artificial Lung Devices Market include:
Xenios AG
Cleveland Heart
Terumo
Sorin Group
Getinge
Abbott Laboratories
Fresenius Medical Care
Medtronic
Asahi Kasei Medical
Toshiba Medical Systems Corporation
LivaNova
Omni Life Science
Market growth is being driven by the increasing prevalence of chronic respiratory diseases, a growing geriatric population, rising healthcare expenditure, and demand for advanced respiratory support. Technological advances in ECMO, membrane oxygenation, miniaturized devices, AI-assisted monitoring, and portable systems are improving treatment efficiency and expanding the potential applications of artificial lung technologies.
The Artificial Lung Devices Market is segmented by Product Type into Extracorporeal Membrane Oxygenation, Invasive Ventilation, Non-Invasive Ventilation, and Oxygenators; by Application into Cardiopulmonary Bypass, Respiratory Failure, Pulmonary Embolism, and Severe Pneumonia; by End User into Hospitals, Specialized Clinics, and Home Care Settings; by Technology into Hybrid Technology, Artificial Intelligence Assisted, and Traditional Technology; and by Region into North America, Europe, South America, Asia Pacific, and Middle East and Africa.
Significant opportunities are emerging from technological advancements, increasing respiratory disease prevalence, growing investment in healthcare innovation, and expanding home-care applications. Wearable artificial lung technologies, biocompatible materials, device miniaturization, and AI-driven predictive analytics could further improve patient mobility, monitoring, and treatment outcomes.
Recent Developments and Market Trends:
Terumo announced the acquisition of Xenios AG in June 2024 to expand its extracorporeal life support portfolio and accelerate next-generation ECMO development.
Getinge announced a strategic collaboration with Medtronic in November 2024 to co-develop next-generation ECMO circuits and integrated hospital software.
Asahi Kasei Medical introduced a new membrane oxygenator in February 2025 for ECMO systems.
AI-assisted technologies are gaining attention for real-time patient monitoring, predictive analytics, and improved artificial lung device efficiency.
Portable artificial lung devices are gaining traction as healthcare systems increasingly seek solutions that can support long-term care and greater patient mobility.
Reasons to Buy the Report:
Understand the current market size and projected growth trajectory of the global Artificial Lung Devices Market.
Identify opportunities across product type, application, end user, technology, and regional segments.
Assess North America’s market leadership and the growth potential of Asia Pacific.
Analyze major companies, competitive strategies, collaborations, acquisitions, and product developments.
Evaluate opportunities created by AI-assisted monitoring, portable devices, ECMO technologies, and expanding home healthcare applications.
Future Outlook:
The Artificial Lung Devices Market is expected to maintain strong growth through 2035 as respiratory diseases, critical-care requirements, and demand for advanced lung-support technologies continue to increase. North America is projected to remain the dominant regional market, rising from USD 1.2 billion in 2024 to USD 2.4 billion by 2035, while Invasive Ventilation is expected to remain the leading product type, growing from USD 700 million to USD 1.4 billion over the same period. Continued advances in ECMO, AI-assisted technologies, portable devices, and biocompatible materials are expected to support the market’s progression to USD 4.5 billion by 2035 at a 7.1% CAGR.
➤➤Explore Our Latest Related Reports:
